GET DAILY SIGNALSFoghorn Therapeutics (FHTX) and the Road to a +95% Move Toward $4.00
Key Takeaways
- The central target of $4.00 is the arithmetic mean of five verified analyst price targets published in October 2026, after a major pipeline reset.
- The latest verified price is about $2.05, so reaching $4.00 would require a gain of roughly 95% — a very large move.
- The individual analyst price targets used range from a low of $2.00 to a high of $5.00, a wide spread that reflects sharp disagreement after FHD-909 was discontinued and the Eli Lilly collaboration ended.
- The strongest supporting factors are the company's cash runway extending into the second half of 2029 and optionality across several wholly owned preclinical and early-stage programs.
- The biggest risks are the loss of the lead clinical asset, limited near-term catalysts, and the need for additional capital or partners to advance the pipeline.
- You can find more information on Foghorn Therapeutics' Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Analyst Price Targets and the Current Consensus
Foghorn Therapeutics Inc. (FHTX) focuses on precision medicines aimed at the chromatin regulatory system. Coverage shifted noticeably in early October 2026 once the company and partner Eli Lilly (LLY) chose not to move the SMARCA2 inhibitor FHD-909 into further clinical expansion. I checked recent notes and found five verifiable targets still in place. Guggenheim, H.C. Wainwright, and Stifel kept Buy ratings at $5.00 (October 1–2, 2026). Evercore ISI shifted to In Line with a $3.00 target (October 13, 2026), and Wedbush went to Neutral at $2.00 (October 2, 2026). The average comes to $4.00, with the range running from $2.00 to $5.00.
That spread captures real differences in outlook. The higher targets reflect value in the remaining wholly owned assets, such as the selective EP300 degrader, an oral inflammation and immunology program, and a selective CBP degrader. More cautious views highlight the loss of the main clinical program and a thinner set of upcoming events. Several other firms, including BTIG, TD Cowen, and Citizens, moved to Hold without new targets, which reads more like a pause than outright negativity.
Where the Stock Stands Today and What It Would Take
Shares have been trading near $2.05, giving the company a market capitalization of roughly $122 million. That places the stock close to its 52-week low of $1.79 and well below the 52-week high of $7.61. Hitting $4.00 from here would mean upside of approximately 95%, a substantial move that would nearly double the current price without fully recovering 2026 losses. I also checked this using Tickeron’s AI Trend Prediction Engine to see how momentum lines up with the fundamentals.
Management has shifted focus to the wholly owned programs following a 40% workforce reduction. That step has extended the cash runway into the second half of 2029, easing near-term financing concerns. Still, turning preclinical work into clinical data remains the key requirement for any re-rating.
Factors That Could Help Close the Gap
Several elements could support progress toward the target. The longer cash runway reduces dilution pressure and gives time to advance earlier programs. Multiple independent assets mean success in any one area could shift sentiment. The shares also appear to trade near net cash in some estimates, which can provide a floor and draw in value-focused investors. New partnerships or licensing deals on the wholly owned programs would add both capital and validation, something analysts on both sides of the debate have noted as important.
Obstacles That Could Keep the Target Out of Reach
The main challenge remains the discontinuation of FHD-909 and the effective end of the Eli Lilly collaboration. With the lead clinical candidate set aside, the catalyst calendar looks thin until around 2028. The remaining programs are still preclinical or early-stage, carrying standard development risks. Recent downgrades from several firms underscore a more guarded view that fresh data or deals will be needed before the stock re-rates. Execution after the workforce reduction adds another layer to watch.
Technical Picture and Key Levels
The stock’s structure weakened sharply through 2026 as the price fell from above $7 to near $2. The $1.79 low stands out as important support, while $2.00 has acted as a psychological floor lately. On the upside, $3.00 lines up with Evercore ISI’s target as an early resistance point, with $5.00 representing a larger hurdle that matches three of the five analyst targets. Reaching $4.00 would require clearing several layers rather than a single clean breakout.
What to Watch Going Forward
Analyst targets generally look out about 12 months. The next earnings report, expected in early November 2026, will likely include updates on cash position, restructuring progress, and pipeline priorities. After that, development-candidate nominations, clinical-trial starts, new partnership announcements, and any further analyst changes will be worth tracking, especially given how quickly targets shifted after the FHD-909 decision.
Monitoring Momentum with AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical patterns. For a name like FHTX that moves on catalysts and technical shifts, these signals can help track momentum changes alongside the fundamental story. I find them useful for spotting evolving trends without replacing deeper research.
Final Assessment
Whether Foghorn Therapeutics (FHTX) can reach $4.00 comes down to how the market balances remaining pipeline optionality against the loss of its lead asset. The $4.00 average of five targets ranging from $2.00 to $5.00 would require a roughly 95% advance from about $2.05. Support rests on an extended cash runway, multiple early programs, and a valuation near net cash, while obstacles include a thin catalyst schedule, execution risk, and divided analyst views. Watching pipeline updates, potential new deals, and further revisions will help clarify the outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FHTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FHTX turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 33 of 35 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FHTX's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on FHTX as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.502) is normal, around the industry mean (3.037). P/E Ratio (-2.071) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement